 | Patient outcomes | - Delayed/misdiagnosis
- Poor prognosis at diagnosis
|  | - Timely diagnosis
- Positive prognosis and treatment outcomes
|
 | Economics | - Redundancy and duplication
- Resource intensive; Limited ROI
| | - Cost-effective and efficient funding
- “Skin in the game” across stakeholders
|
 | Commercial implications | - Lack of clarity on “real” epidemiology
- Slow uptake curves
| | - Improved view on number and spread of patients
- Targeted patient journey strategies
|
 | Research implications | - Smaller, fragmented datasets
- Limited genotype/phenotype understanding
| | - Big data ready databases
- Increased natural history of disease understanding
- Improved genotype/phenotype knowledge
|
